ACHL | Achilles Therapeutics plc

Healthcare | Biotechnology | United Kingdom | NASD

Index	-	P/E	-	EPS (ttm)	-1.81	Insider Own	5.96%	Shs Outstand	39.73M	Perf Week	1.74%
Market Cap	40.51M	Forward P/E	-	EPS next Y	-1.21	Insider Trans	0.00%	Shs Float	38.91M	Perf Month	24.65%
Income	-71.30M	PEG	-	EPS next Q	-0.41	Inst Own	73.60%	Short Float / Ratio	0.04% / 0.08	Perf Quarter	-4.93%
Sales	-	P/S	-	EPS this Y	14.70%	Inst Trans	0.50%	Short Interest	0.01M	Perf Half Y	-49.63%
Book/sh	4.66	P/B	0.22	EPS next Y	13.60%	ROA	-31.20%	Target Price	8.80	Perf Year	-59.47%
Cash/sh	3.98	P/C	0.26	EPS next 5Y	3.20%	ROE	-34.90%	52W Range	0.75 - 3.45	Perf YTD	13.04%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-70.51%	Beta	-
Dividend %	-	Quick Ratio	10.30	Sales past 5Y	-	Gross Margin	-	52W Low	35.65%	ATR	0.07
Employees	234	Current Ratio	10.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	56.49	Volatility	7.28% 7.48%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	1.30%	Profit Margin	-	Rel Volume	0.20	Prev Close	1.03
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Mar 07 BMO	Payout	-	Avg Volume	180.60K	Price	1.02
Recom	1.80	SMA20	2.73%	SMA50	9.68%	SMA200	-34.26%	Volume	35,916	Change	-1.22%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-26-21	Initiated	Piper Sandler	Overweight	$25
Apr-26-21	Initiated	Oppenheimer	Outperform	$23
Apr-26-21	Initiated	JP Morgan	Underweight	$11
Apr-26-21	Initiated	Chardan Capital Markets	Buy	$27
Apr-26-21	Initiated	BofA Securities	Buy	$20

May-21-23 10:03AM	3 Stocks With 1,000% Upside Potential (InvestorPlace)
May-10-23 07:15AM	Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
07:00AM	Achilles Therapeutics New Immunogenicity Prediction Application of its AI-Powered PELEUS Platform Uniquely Identifies the Most Potent T Cell Antigens (GlobeNewswire)
Apr-25-23 06:00PM	Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement (GlobeNewswire)
07:00AM	Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status (GlobeNewswire)
09:45AM	Loading…
Apr-22-23 09:45AM	Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Apr-17-23 08:00AM	Achilles Therapeutics to Present at Chardans 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit (GlobeNewswire)
Mar-07-23 07:00AM	Achilles Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-02-23 09:40AM	Is Achilles Therapeutics (ACHL) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-17-23 09:40AM	Is Anika Therapeutics (ANIK) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-20-22 08:30AM	Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-06-22 06:00AM	Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022 (GlobeNewswire) -12.28%
Nov-30-22 06:05PM	Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022 (GlobeNewswire) +6.32%
Nov-22-22 08:00AM	Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary Method (GlobeNewswire)
Nov-13-22 07:48AM	Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
07:00AM	Loading…
Nov-08-22 07:00AM	Achilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) -10.05%
Nov-01-22 12:00PM	What Makes Achilles Therapeutics PLC Sponsored ADR (ACHL) a New Buy Stock (Zacks)
Oct-06-22 08:30AM	Achilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal Nature of Neoantigens as Targets in Cancer Cell Therapy (GlobeNewswire)
Sep-07-22 01:15PM	Gilead's (GILD) Tecartus Gets EC Nod for New Cancer Indication (Zacks)
Aug-31-22 12:53PM	Curis (CRIS) Gets FDA Nod to Partly Resume Leukemia Study (Zacks)
Aug-26-22 01:34PM	Kodiak Sciences (KOD) Rises 60% in Past 3 Months: Here's Why (Zacks)
Aug-25-22 11:53AM	AstraZeneca (AZN) Gets Japan Nod for Expanded Use of 3 Drugs (Zacks)
Aug-24-22 01:33PM	Amgen (AMGN) Posts Positive Data from Soliris' Biosimilar Study (Zacks)
Aug-23-22 01:53PM	Horizon (HZNP) Marketed Drugs Aid Growth, Stiff Rivalry a Woe (Zacks)
Aug-19-22 12:32PM	Kodiak Sciences (KOD) Focuses on Developing Eye Drug Tarcocimab (Zacks) -7.76%
Aug-16-22 10:09AM	Horizon (HZNP) Inks Collaboration Deal with Q32 Bio for ADX-914 (Zacks)
Aug-09-22 07:00AM	Achilles Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-01-22 06:00AM	What Is The Ownership Structure Like For Achilles Therapeutics plc (NASDAQ:ACHL)? (Simply Wall St.)
Jul-21-22 08:00AM	Achilles Therapeutics to lead Horizon Europe-Funded Consortium to Advance Personalized Cell Therapy Manufacturing (GlobeNewswire)
Jun-30-22 08:00AM	Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board (GlobeNewswire)
08:30AM	Loading…
Jun-21-22 08:30AM	Achilles Therapeutics Recognized with the 2022 PING Innovation Award (GlobeNewswire)
Jun-06-22 08:40AM	Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation (Simply Wall St.)
May-10-22 07:00AM	Achilles Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) +5.10%
May-09-22 07:00AM	Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma (GlobeNewswire) -9.26%
May-04-22 08:00AM	Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors (GlobeNewswire)
May-03-22 08:00AM	Achilles Therapeutics to Present at Upcoming Conferences (GlobeNewswire) +7.24%
Apr-14-22 11:27AM	Center for Breakthrough Medicines' latest deal is with London biotech firm Achilles Therapeutics (American City Business Journals) -7.78%
Apr-12-22 07:30AM	The Center for Breakthrough Medicines (CBM) Strikes Multi-Year Deal with UK Cell Therapy Powerhouse (PR Newswire) -10.39%
07:30AM	Achilles Therapeutics Announces Manufacturing Expansion in the UK and Partnership for Manufacturing in the US (GlobeNewswire)
Apr-05-22 08:00AM	Achilles Therapeutics to Present at Upcoming Conferences (GlobeNewswire) -7.57%
Apr-04-22 08:00AM	Achilles Therapeutics to Host KOL Webcast to Highlight TRACERx Study Presentations from the 2022 AACR Annual Meeting (GlobeNewswire)
Mar-08-22 08:00AM	Achilles Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference (GlobeNewswire)
Mar-01-22 09:00AM	Achilles Therapeutics Selects Netralitys 401 North Broad for United States Headquarters (GlobeNewswire) -7.25%
07:02AM	Achilles Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Business Highlights (GlobeNewswire)
04:00AM	London-based Achilles Therapeutics picks Philadelphia for its first U.S. location (American City Business Journals)
Feb-07-22 07:30AM	Achilles Therapeutics Strengthens Scientific Advisory Board with Appointment of Alena Gros, Ph.D. and Ben Creelan, M.D. (GlobeNewswire)
Jan-13-22 07:30AM	Achilles Therapeutics Provides Business Update and Outlook for 2022 (GlobeNewswire) -6.03%
Dec-28-21 04:09AM	Achilles Therapeutics (NASDAQ:ACHL) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Dec-21-21 08:00AM	Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.65%
Dec-20-21 08:00AM	Achilles Therapeutics Added to the NASDAQ Biotechnology Index (GlobeNewswire)
Dec-09-21 07:00AM	Achilles Therapeutics Presents Positive Data at ESMO I-O Congress 2021 on High-Dose Manufacturing Process for Precision T Cell Therapies Targeting Clonal Neoantigens (GlobeNewswire) -6.58%
Nov-12-21 07:00AM	Achilles Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Demonstrating the Ability to Detect, Quantify and Track Patient-specific cNeT and Significant Increase in cNeT Dose from VELOS Process 2 Manufacturing (GlobeNewswire) -5.07%
Nov-10-21 08:15AM	Secarna Pharmaceuticals and Achilles Therapeutics Sign Research, Option and License Agreement to Develop Optimized T Cell Therapies (ACCESSWIRE)
Nov-09-21 08:00AM	Achilles Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-22-21 07:30AM	Achilles Therapeutics Presents Data at the 2021 European Society for Gene and Cell Therapy (ESGCT) Congress Demonstrating its Proprietary Manufacturing Process Can Generate Potent, Personalized Anti-Cancer Cell Therapy Candidates in Multiple Solid Tumor Types (GlobeNewswire) -8.61%
Oct-12-21 08:00AM	Achilles Therapeutics to join the Northern Alliance Advanced Therapy Treatment Centre consortium (GlobeNewswire) +7.00%
Oct-01-21 08:00AM	Achilles Therapeutics to Present at Upcoming Scientific Congresses (GlobeNewswire)
Sep-29-21 06:15AM	Here's What Achilles Therapeutics plc's (NASDAQ:ACHL) Shareholder Ownership Structure Looks Like (Simply Wall St.) -5.04%
Sep-02-21 08:30AM	Achilles Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-25-21 08:00AM	Achilles Therapeutics Announces Grant of US and European Patents (GlobeNewswire)
Aug-10-21 07:00AM	Achilles Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights (GlobeNewswire) +22.13%
Jul-26-21 03:00PM	Is Achilles Therapeutics plc (ACHL) A Good Stock To Buy? (Insider Monkey)
Jul-01-21 08:00AM	Achilles Therapeutics Enrolls First US Patient in Ongoing Phase I/IIa Study in Advanced Non-small Cell Lung Cancer (GlobeNewswire)
04:40AM	We Think Achilles Therapeutics (NASDAQ:ACHL) Can Afford To Drive Business Growth (Simply Wall St.)
Jun-04-21 09:00AM	Achilles Therapeutics Details Phase I/IIa Clinical Trial Design of CHIRON in Patients with Advanced Non-Small Cell Lung Cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-11-21 07:00AM	Achilles Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Highlights (GlobeNewswire)
May-06-21 08:00AM	Achilles Therapeutics Receives Horizon 2020 Grant as Part of Neoantigen Consortium (GlobeNewswire) -10.07%
May-05-21 08:30AM	Achilles Therapeutics to present at the BofA Securities 2021 Virtual Healthcare Conference (GlobeNewswire)
May-03-21 08:00AM	Achilles Therapeutics Appoints Julie ONeill to Board of Directors and Markwin Velders, Ph.D. joins Scientific Advisory Board (GlobeNewswire)
Apr-10-21 08:30AM	Achilles Therapeutics Demonstrates cNeT Product Characterization and Post-Infusion Tracking in a Patient Case Study at the American Association for Cancer Research (AACR) 2021 Annual Meeting (GlobeNewswire)
Apr-06-21 04:01PM	Achilles Therapeutics Announces Closing of $175.5 million Initial Public Offering (GlobeNewswire) +19.71%
Mar-31-21 02:01PM	Two Companies Went Public Today. One Climbed, the Other Dropped. (Barrons.com)
Mar-30-21 07:00PM	Achilles Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACHL | Achilles Therapeutics plc

Upgrade your FINVIZ experience